ECS Botanics Secures a $24 Million Offtake Agreement with MediCann Health for Supply of Medicinal Cannabis

ECS Botanics Secures a $24 Million Offtake Agreement with MediCann Health for Supply of Medicinal Cannabis


ECS Botanics Holdings Ltd (ASX: ECS) (“ECS” or the “Company”) is pleased to advise that it hassecured a binding offtake agreement (“Medicann Offtake Agreement”) to supply medicinal cannabisdried flower over the next five years to MediCann Health. Under the Medicann Offtake Agreement,ECS will supply $24 million of pharmaceutical-grade cannabis dried flower to Perth-based medicinalcannabis company MediCann Health Pty Ltd (“MediCann”) beginning in January 2024. Both ECS andMedicann expect the volumes ordered under the Offtake Agreement to exceed the minimum annualvolumes.

The new Medicann Offtake Agreement follows ECS Botanics securing two binding offtakeagreements in June 2023 (see ASX announcements dated 26 June 2023), underscoring theCompany's strong presence in the B2B sector and highlighting the positive outcomes stemming fromits recent capacity and production enhancements. New protective cropping enclosures andproduction enhancements have been aimed at bolstering crop yields across additional outdoor fieldsand extending growing seasons through improvements to protective cropping enclosures.

MediCann is a leading medicinal cannabis healthcare company that provides patients with access tolocal specialist doctors and pharmacists who have experience prescribing cannabis-basedmedication. Under the offtake agreement, ECS will continue to exclusively supply two strains of GMPmedicinal cannabis dried flower to MediCann.

Commenting on the agreement, ECS Managing Director, Nan-Maree Schoerie said:

"We are excited to announce the expansion of our partnership with MediCann through this newlyextended, long-term supply agreement. MediCann's dedication to putting patients at the forefront of theirbusiness aligns perfectly with our own commitment to delivering top-tier medicinal cannabis. Ourexpertise in cultivating and manufacturing cannabis, combined with our shared focus on patient well-being, inspires us to continue to provide outstanding medicine to companies such as MediCann. Thisagreement not only reinforces our dedication to meeting the growing demand for affordable, accessible, and effective medicinal cannabis products but also marks another milestone following our June 2023agreements, totalling $11.9 million. These partnerships highlight the strong local demand for our GMPcertified, pharmaceutical-grade cannabis and provide ECS with a solid foundation to continue to deliverprofitable growth."

MediCann Founder and CEO, Matt Shales said:

"It has been highly rewarding to work closely with ECS over the past number of years and we aredelighted to strengthen our partnership even further as we secure an exclusive long-term supplyagreement with ECS Botanics for its high-quality Australian grown flowers. We look forward tocontinuing our mission to improve the quality of life of people in need of these products and to continueto build on our partnership with ECS Botanics for the long term."

Key terms of the Medicann Offtake Agreement

The Medicann Offtake Agreement commences on 1 January 2024, until which time Medicann Healthwill continue to be supplied medicinal cannabis dried flower under the current agreement. The OfftakeAgreement stipulates annual volumes of each ECS developed strain that will be supplied exclusivelyby ECS to Medicann Health. Should Medicann not purchase such volumes it will be liable for 80% ofsuch volume not purchased in any calendar year. Termination of, or changes to, the Medicann OfftakeAgreement require mutual agreement.

Authorised on behalf of ECS Botanics Holding Ltd by Nan-Maree Schoerie, Managing Director.

About ECS Botanics Holdings Ltd

ECS Botanics Holdings Ltd is an Australian medicinal cannabis cultivator and manufacturer located in NorthwestVictoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in asustainable way, adopting regenerative and organic horticultural practices and renewable energy sources.Licenced by the Australian Therapeutic Goods Administration to manufacture GMP (equivalent to PIC/S, EUagencies are all PIC/S members) certified products, ECS has become a leading provider of high quality, affordablemedicinal cannabis.

For further information, please contact: info@ecs-botanics.com

Source

The Conversation (0)

U.S. Cannabis Market Soars Amid Legal Reforms, But Safety Concerns Persist

-

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Trulieve Announces Opening of Affiliated Medical Marijuana Dispensary in Wilkes-Barre, Pennsylvania

New dispensary expands patient access to medical marijuana with ribbon cutting and pop-up event

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing marijuana company in the U.S., today announced the opening of a new Trulieve-affiliated medical marijuana dispensary in Wilkes-Barre, Pennsylvania .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Gulf Breeze, Florida

New Santa Rosa County location will host grand opening celebration Friday, July 12th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Gulf Breeze, Florida .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Cannabis Corp. to Hold Second Quarter 2024 Results Conference Call on August 6, 2024

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., will hold a conference call on Tuesday, August 6, 2024 at 8:30 AM Eastern Time following the release of its second quarter 2024 financial results.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

Chairman, Founder, and Chief Executive Officer Kim Rivers and Chief Financial Officer Wes Getman will participate on the call to review Trulieve's financial and operating results.

Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call and ask to join the Trulieve Cannabis Corp. call.

North American toll free: 1-844-824-3830

Passcode:

1732811

International: 1-412-542-4136

Passcode:

1732811

A live audio webcast of the conference call will be available at:
Trulieve Second Quarter 2024 Results Call

An archived replay of the webcast will be available at:
https://investors.trulieve.com/events

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-cannabis-corp-to-hold-second-quarter-2024-results-conference-call-on-august-6-2024-302191314.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2024/09/c4702.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Hygrovest Limited

HGV Appendix 4D - Half Year Report

Hygrovest Limited (ASX:HGV) ("HGV")is an Australian-listed specialist investment company which concentrates on producing capital growth for shareholders over the medium to long term from investments in listed and unlisted equities and other financial assets.

HGV encloses the Appendix 4D and financial statements in respect of the half year ended 31 December 2021 lodged in accordance with ASX LR4.2B.

Keep reading...Show less

Cronos Group Inc. to Reconvene Virtual 2024 Annual Meeting of Shareholders

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") announced today that it will reconvene its 2024 Annual Meeting of Shareholders on Friday, July 19, 2024, at 11:00 a.m. ET.

Cronos will be conducting the reconvened meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the reconvened 2024 Annual Meeting online regardless of their geographic location, including a chance to ask questions and vote.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×